



Universiteit
Leiden
The Netherlands

Genetic, clinical and experimental aspects of restenosis : a biomedical perspective

Monraats, P.S.

Citation

Monraats, P. S. (2006, June 6). *Genetic, clinical and experimental aspects of restenosis : a biomedical perspective*. Retrieved from <https://hdl.handle.net/1887/4405>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4405>

Note: To cite this publication please use the final published version (if applicable).

GENETIC, CLINICAL AND EXPERIMENTAL ASPECTS OF RESTENOSIS

-A biomedical perspective-

GENETIC, CLINICAL AND EXPERIMENTAL ASPECTS OF RESTENOSIS

-A biomedical perspective-

PROEFSCHRIFT

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden
op gezag van de Rector Magnificus Dr. D.D. Breimer,
Hoogleraar in de faculteit der Wiskunde
en Natuurwetenschappen en die der Geneeskunde,
volgens het besluit van het College voor Promoties
te verdedigen op dinsdag 6 juni 2006
te klokke 14.15 uur

door
Pascalie Stéphanie Monraats
geboren te 's-Gravenhage
in 1979

Promotiecommissie

Promotores:

Prof. dr. J.W. Jukema
Prof. dr. A.H. Zwinderman
(Academisch Medisch Centrum, Amsterdam)

Referent:

Prof. dr. Y. Pinto
(Academisch Ziekenhuis Maastricht)

Overige commissieleden:

Prof. dr. A. van der Laarse
Prof. dr. E.E. van der Wall
Prof. dr. M.J. Schalij
Prof. dr. R.R. Frants
Prof. dr. P.A.F.M. Doevendans
(Universitair Medisch Centrum Utrecht)
Dr. P.H.A. Quax
Dr. M.P.M. de Maat
(Erasmus Medisch Centrum, Rotterdam)

The research described in this thesis was performed at the Department of Cardiology (Head: Prof. dr. E.E. van der Wall) of the Leiden University Medical Center, Leiden, the Netherlands

Financial support by the Netherlands Heart Foundation for the publication of this thesis is gratefully acknowledged.

The study described in this thesis was supported by a grant of the Netherlands Heart Foundation (NHF- 99.210), by the Center for Medical Systems Biology (CMSB) and a grant from the Interuniversity Cardiology Institute of the Netherlands (ICIN).

*“But there is no possible knowledge,
which arrives not from a pre-existent knowledge”*

William Harvey MD, 1578-1657

Voor mijn ouders

Colofon

© 2006 P.S. Monraats, Leiden, The Netherlands

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission from the copyright owner.

ISBN: 90-9020637-X

ISBN: 978-90-9020637-0

Lay-out: D.E. Samama

Cover by: M. Lucas and S. de Blik

Represents: The Linkage disequilibrium (LD) structure of the TNF gene in Caucasians

Printed by: Febodruk B.V. te Enschede, The Netherlands

The publication of this thesis has been kindly supported by:

Jacques H. de Jong Stichting

Medtronic Trading Nederland B.V.

Guidant Nederland B.V.

St. Jude Medical Nederland B.V.

Sorin Group Nederland B.V.

Pfizer Nederland B.V.

Merck Sharp & Dohme B.V.

Boehringer Ingelheim B.V.

Bristol-Myers Squibb B.V.

AstraZeneca B.V.

Sankyo-pharma Nederland B.V.

Table of Contents

Chapter 1	9
General introduction and outline of the thesis	
Chapter 2	19
Genetic predictive factors in restenosis. <i>Pathol Biol (Paris)</i> . 2004 May;52(4):186-95. Review	
Chapter 3	43
Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. <i>Eur Heart J</i> . 2004 Jul;25(13):1163-70	
Chapter 4	65
Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. <i>Diabetes Care</i> . 2005 Apr;28(4):873-7	
Chapter 5	79
Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. <i>Circulation</i> . 2005 Oct;112(16):2417-25	
Editorial: Genomics of In-Stent Restenosis. <i>Circulation</i> . 2005 Oct;112:2378-2379	
Chapter 6	105
-455 G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. <i>Thromb Haemost</i> . 2005 Mar;93(3):564-9	
Chapter 7	121
Lipoprotein Lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention. <i>J Am Coll Cardiol</i> . 2005 Sep;46(6):1093-100	
Chapter 8	141
Tumor Necrosis Factor- α plays an important role in restenosis development. <i>FASEB J</i> . 2005 Dec;19(14):1998-2004	
Chapter 9	159
Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary intervention. <i>Pharmacogenet Genomics: in press</i>	
Chapter 10	179
Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. (submitted)	
Summary and conclusions	197
Samenvatting en conclusies	203
List of publications	211
Curriculum Vitae	215
Dankwoord	217
Full color figures	219

